Technology | May 13, 2015

Abbott, GE Healthcare Partner to Identify Source of Atrial Fibrillation

Integrated system brings together real-time patient data for assisting in faster analysis of complex heart rhythm disorders

Abbott, GE, CardioLab, RhythmView, atrial fibrillation, source

GE's CardioLab is one half of the integrated system with Abbott that will provide patient-specific data on the heart's electrical activity in real time.


May 13, 2015 — Abbott and GE Healthcare announced an agreement that will bring real-time, patient-specific data about the heart's electrical activity to cardiac electrophysiology labs. The goal of the collaboration is to speed up the diagnosis of the sources of atrial fibrillation and other heart rhythm disorders.

The integration of electrogram signal data from GE's CardioLab electrophysiology recording system into Abbott's RhythmView mapping software will allow doctors to use instantaneous electrical data of a person's heart to identify the sources of atrial fibrillation. By providing patient-specific diagnostics based on each person's unique physiology, this integrated system transforms current treatment approaches, which primarily rely on a one-size-fits-all anatomical approach.

Abbott's mapping software, or rotor identification system, helps physicians identify and target the specific areas of a person's heart that are perpetuating atrial fibrillation, the most common heart rhythm disorder. Abbott entered the catheter-based electrophysiology market last year through the acquisition of Topera Inc.

GE Healthcare’s CardioLab helps simplify the electrophysiology practice and streamline the workflow in diagnosis and treatment of complex cardiac cases.

For more information: www.abbott.com


Related Content

News

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular ...

Home April 29, 2026
Home
News

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT) ...

Home April 27, 2026
Home
News

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation ...

Home April 27, 2026
Home
News

April 13, 2026 — Johnson & Johnson has announced favorable 12-month interim effectiveness and safety results from ...

Home April 13, 2026
Home
News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
Subscribe Now